Ac­ne was a bust, but ex­ces­sive sweat­ing scores FDA OK for Der­mi­ra — shares climb

Af­ter a cat­a­stroph­ic fail­ure in ac­ne that oblit­er­at­ed its stock just months ago, Der­mi­ra $DERM had some re­deem­ing news this morn­ing — the FDA has OK’ed its an­ti-sweat­ing drug gly­copy­rro­ni­um.

The med now goes un­der the brand name Qbrexza, and it’s a once-dai­ly, top­i­cal treat­ment for peo­ple with ex­ces­sive un­der­arm sweat­ing (al­so called pri­ma­ry ax­il­lary hy­per­hidro­sis). The treat­ment is ap­plied di­rect­ly to the skin, block­ing sweat gland ac­ti­va­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.